Four types of aescin that are available on the pharmaceutical market, β-aescin crystalline, β-aescin amorphous, β-aescin sodium and aescin polysulfate, have been analyzed for their cytotoxic effects on human colon adenocarcinoma (LoVo) and doxorubicin-resistant human colon adenocarcinoma cell lines (LoVo/Dx). Their cytotoxic activities were evaluated by sulforhodamine B (SRB) and methyl tetrazolium (MTT) assays. All four types of aescin exerted strong dose-dependent cytotoxicity to LoVo and, to a lesser degree, LoVo/Dx cell lines. The IC 50 value for the LoVo/Dx cell line was higher, but still dosedependent. Results from both assays demonstrated that β-aescin crystalline has the most cytotoxic activity toward human colon adenocarcinoma cell lines.
Colorectal cancer (CRC) is the second most frequent malignant disease in Europe and the third most commonly diagnosed cancer in the United States. The incidence of CRC is generally higher for men, and the risk of the disease increases with age, as the majority of cases are diagnosed in patients more than 50 years of age. Colorectal cancer develops through a multistep process in which normal mucosa is first transformed into adenomatous polyps and then eventually into invasive carcinoma [1, 2] .
Aescin (aescine or escin) is a natural mixture of triterpene saponins extracted from the seeds of horse chestnut (Aesculus hippocastanum L., Hippocastanaceae). The aglycons are derivatives of protoascigenin or barringtogenol C acylated by acetic acid at C-22 and esterified with tiglic acid, angelic acid, α-methylbutyric acid or isobutyric acid at C-21. Aescin exists in two forms, α and β, which can be distinguished by melting point, specific rotation, hemolytic index and solubility in water. β-Aescin appears to be the active component of the mixture and is the molecular form present in the major available pharmaceutical products. It has been reported that β-aescin exhibits anti-edematous, anti-inflammatory and venotonic properties [3] [4] . Different types of aescins are available including β-aescin sodium, β-aescin amorphous and aescin polysulfate. Besides its topical application there are many drugs and dietary supplements that contain either aescin or extracts of horse-chestnut rich in aescin that are administrated orally.
Recently β-aescin has been shown to inhibit proliferation and induce apoptosis of various types of cancer and endothelial cells [5] [6] [7] . β-Aescin sodium has been demonstrated to downregulate the activity of p38 MAPK kinase and inhibit the proliferation of A 549 cells [8] . Other authors have reported that β-aescin sodium decreased inducible nitric oxide synthase (iNOS) expression in A 549 cells by inhibiting the phosphorylation and nuclear translocation of STAT1 and STAT3 [9] . Some interesting work has been carried out on LPS-induced endotoxemic mice in validating the anti-inflammatory properties of aescin [10] . In this study inhibition of serum aminotransferases activity, significant reduction of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and nitric oxide (NO) by aescin were demonstrated. Moreover, the major mechanisms have been clarified of aescin sodium in the treatments of chronic venous insufficiency (CVI) including varicose veins and lower extremity venous ulcers [11] . Aescin was also shown to chemosensitize human tumor cells through inhibition of the Nuclear Factor-κB signaling pathway [12] . Many reports have been focused on the action of β-aescin sodium as a potent natural inhibitor of proliferation and inducer of apoptosis in different cell lines [5] [6] [7] .
HPLC analysis was performed in order to compare qualitatively the investigated aescin types according to the method in Pharmeuropa for horse-chestnut [13] . The obtained types of aescin were studied in vitro for their cytotoxicity against human colorectal adenocarcinoma (LoVo) and doxorubicin-resistant cell lines (LoVo/Dx). To detect the cytotoxic effects of aescin polysulfate, β-aescin crystalline, β-aescin amorphous and β-aescin sodium on LoVo cells, the cells were incubated with different doses of aescin for 48 h and then MTT assays were performed. The MTT results showed that aescins depressed the proliferation of LoVo cells in a dose-dependent manner (Figures 1-4 ). The most cytotoxic effect was shown by β-aescin crystalline (IC 50 16.6 µg/mL for 48 h exposure). The IC 50 concentrations were 43.2 µg/mL for aescin sodium, 38.8 µg/mL for aescin polysulfate, and 39.0 µg/mL for aescin amorphous. For comparison we used a doxorubicin resistant LoVo subline (LoVo/Dx), which expresses a high level of the mdr-1mRNA encoding for the P-glycoprotein [14] . The IC 50 at 48 h post incubation of β-aescin crystalline was 28.2 µg/mL. The equivalent values were 46.4, 58.2 and 62.7 µg/mL for aescin sodium, aescin polysulfate and aescin amorphous, respectively. The SRB assay corroborated these results and showed that aescins treatment resulted in a concentration-dependent inhibition of cell viability. After 48 h incubation, the IC 50 for LoVo cells was the lowest (18.7 µg/mL) for β-aescin crystalline, as well as for LoVo/Dx cells.
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In recent years a relatively large number of publications devoted to various aspects of saponins analysis also contained some reference to their biological activity [15] . Recent research indicates that saponins have antitumor effects on many cancer cells. Several saponins inhibit tumor cell growth by cell cycle arrest and apoptosis with IC 50 values up to 0.2 mM. Moreover, saponins in combination with conventional tumor treatment strategies result in improved therapeutic success. Correlations between the structure and the cytotoxicity of saponins have been described, as well as the most common mechanisms of action [15, 16] . Aescin, a natural mixture of triterpene saponins, has been used in the clinic for many years. Presently different types of aescin are more readily available and affordable than some new drugs. Most of the cancer cell lines tested are sensitive to aescin sodium [6] [7] [17] [18] . However, the mechanisms by which this elicits its chemopreventive properties remain largely unknown. MTT assay was used to determine cytotoxicity because only metabolically active cells can reduce the salt to its formazan product. Nevertheless, this method has limitations. The formation of color relies on the activity of the mitochondria so, if the function of these is inhibited by other factors, such as glucose and NADH in cells, variable results are obtained. Because of these limitations we used the second major technique for testing cytotoxicity. This assay (SRB) relies on the uptake of the negatively charged dye, sulphorhodamine B by basic amino acids in the cells. The greater the number of cells, the greater amount of dye is taken up. However, our experimental results obtained by both methods are comparable. We report here that not only β-aescin sodium has a cytotoxic effect on LoVo cells, but also other types that differ mostly in their water solubility, like β-aescin crystalline, β-aescin polysulfate and β-aescin amorphous. On one hand the presented aescin types are very similar, but with individual differences in HPLC peak intensities, but on the other hand the chromatograms demonstrate a complexicity, making us unable to indicate the most active single compound. Although these data do not express a real quantification, however they can be used to compare the relative quantities of each component. These results suggest that the respective types of aescin have a potential for the prevention and treatment of cancer. Several studies on animals suggest that aescin is well tolerated and has, in addition, an anti-inflammatory effect [19] [20] . Our research opens a new perspective for further investigations.
It has been shown that saponin and flavonoid extracts obtained from ginseng root have an inhibitory effect on the activity of glycoprotein P [21] , a membrane-associated active transport protein which hydrolyzes ATP to pump out of the cell different chemotherapeutic agents, thus conferring multiple resistance to tumor cells [14] . Our paper reports that β-aescins inhibit the growth of a cell line resistant to doxorubicin (LoVo/Dx), as well as to one that is normally sensitive to cytostatics (LoVo). Substances displaying such
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properties could be used to enhance the effect of chemotherapeutic agents with a low risk of inducing side effects, like toxicity towards normal cells.
Experimental
Chemicals: β-Aescin crystalline, β-aescin amorphous and aescin polysulfate were kindly supplied by Noblius Ent (Warsaw, Poland) and β-aescin sodium by Labor (Wroclaw, Poland). Trichloroacetic acid (TCA), dimethyl sulfoxide (DMSO), sulforhodamine B and 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) were purchased from Sigma-Aldrich® GmbH, Germany. Fetal bovine serum (FBS) was purchased from Gibco, and L(+)glutamine from BDH Prolabo. Dulbecco's modified Eagle's medium F12 Ham, cell dissociation solution non-enzymatic, doxorubicin hydrochloride and Antibiotic Antimycotic Solution were purchased from Sigma-Aldrich® GmbH, Germany.
Cell culture: Human colon adenocarcinoma cell line (LoVo) and resistant human colon adenocarcinoma cell line (LoVo DX) were obtained from the Institute of Immunology and Experimental Therapy (Polish Academy of Sciences, Wroclaw Poland). Both cell lines were grown in Dulbecco's medium supplemented with 10% FBS, L-glutamine and antibiotic solution. LoVo/Dx cells were grown in the presence of doxorubicin (100 ng/mL) at 37°C in a humidified atmosphere of 5% CO 2 . In the log-phase of growth the cells were removed from the flask surface with non-enzymatic cell dissociation solution. The density of cells in suspension was determined using a Bruker hemocytometer (usually about 106/mL).
Sulforhodamine B (SRB) assay:
The studied compounds were dissolved in dimethylsulfoxide (DMSO). The concentration of DMSO did not exceed 0.5% in the medium. Cell viability was determined using the sulphorhodamine B (SRB) assay [22] , with minor modifications. The cells (4 x104 cells per well) were seeded into 96-well plates in 75 µL of medium and allowed to attach during a 60 min incubation period at 37°C. Then, 5, 10, 25, 50, 100 µg/mL of the studied β-aescins was added to the medium and the cells were incubated for 48 h. Subsequently, the cells were incubated with 50 µL of 50% ice-cold trichloroacetic acid for 1 h at 4°C. After washing with distilled water 10 times, the cells were stained with 50 µL sulphorhodamine solution (0.4%) at room temperature for 30 min in darkness. The unbound dye was removed by several washes with 1 % acetic acid and each well of the plate was dried. To solubilize the bound SRB, 150 µL of 10 mM Tris base (pH 10.5) was added. The absorbance was measured at 492 nm using a scanning spectrophotometer (Labsystem Multiscan MS Type 352). The experiments were repeated 3 times. The optical density (OD) of SRB in each well is directly proportional to the cell number so the absorbance values could be plotted against concentration. Dose-response curves were generated and the IC 50 values were calculated from the linear portion of the log doseresponse curves.
MTT assay: The LoVo and LoVo/Dx cells were seeded in sterile 96-well microtiter plates at 2 x 104 cells per well. The cells were divided into a control group and an experimental group treated with appropriate β-aescin concentrations (5, 10, 25, 50 and 100 µg/mL). After culturing for 48 h at 37°C in a humidified atmosphere of 5 % CO 2 , MTT solution 20 µL (5 mg/mL) was added to each well. The cell culture incubation was continued for another 2 h at 37°C. After this step, 100 µL of lysis buffer (20 % sodium dodecyl sulfate and 50 % dimethylformamide) was added, and incubation was continued overnight at 37°C. The optical density at 570 nm was measured with a scanning spectrophotometer (Labsystem Multiscan MS Type 352). The experiments were repeated 3 times with triplicates of each measurement point. Controls included wells with untreated cells, wells without cells and the cytotoxic compound doxorubicin. Dose-response curves were generated and the IC 50 values were calculated from the linear portion of the log doseresponse curves.
Analytical HPLC conditions:
All samples were dissolved in MeOH except for aescin polysulfate, which was solved in water with a final concentration of 5 mg/mL. The HPLC apparatus consisted of a Knauer Smartline series (Knauer, Berlin, Germany), a quaternary pump with vacuum degasser, and a Smartline PDA detector 2800. Separation was achieved on a Hypersil Gold C-18 column (250 × 4.6 mm) of 5 μm particle size (Thermo Fisher Scientific Inc., MA, USA). The gradient elution system consisted of aqueous 0.05 % trifluoroacetic acid (mobile phase A) and acetonitrile (mobile phase B). The program elution was set according to the method described by Pharmeuropa [13] with a flow rate at 1.0 mL/min and UV/Vis/NIR detection at 190-1020 nm. The injection volume was 20 μL and chromatograms were recorded at 210 nm. Under these conditions aescin polysulfate was not well separated and was eluted as a broad uneven peak at the beginning of the chromatogram (data not shown). All analyses were carried out isothermally at 25°C in a heated chamber. Before use the mobile phases were degassed by sonication.
